The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy

QR Code

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy

Cancer immunotherapy is a new therapeutic strategy for cancer treatment that targets tumors by improving or restoring immune system function. Therapies targeting immune checkpoint molecules have exerted potent anti-tumor effects and prolonged the overall survival rate of patients. However, only a sm...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Xin Xie, Jingwen Lv, Wei Zhu, Chao Tian, Jingfeng Li, Jiajia Liu, Hua Zhou, Chunyang Sun, Zongfeng Hu, Xiaopeng Li
Format:	article
Langue:	EN
Publié:	Elsevier 2022
Sujets:	Oncolytic virus HSV-1 IL-12 PD-1 antibody Cancer immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/fa02f758bc344d9cb6d0c4f44a8890f4
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
par: Masmudur M. Rahman, et autres
Publié: (2021)

Oncolytic Virotherapy
Publié: (2016)

SELECTED ASPECTS OF ALLO- AND XENOGRAFT MODEL APPLICATIONS FOR DEVELOPING NOVEL ANTI-CANCER VACCINES AND ONCOLYTIC VIRUSES
par: T. S. Nepomnyashchikh, et autres
Publié: (2019)

USP18 and USP20 restrict oHSV-1 replication in resistant human oral squamous carcinoma cell line SCC9 and affect the viability of SCC9 cells
par: Ruitao Lu, et autres
Publié: (2021)

Single-cell RNA sequencing reveals a strong connection between Gadd45g upregulation and oncolytic HSV infection in tumor tissue
par: Divya Ravirala, et autres
Publié: (2021)

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
par: Jiang Q, et autres
Publié: (2021)

An Agent-Based Model of Combination Oncolytic Viral Therapy and Anti-PD-1 Immunotherapy Reveals the Importance of Spatial Location When Treating Glioblastoma
par: Kathleen M. Storey, et autres
Publié: (2021)

The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors
par: Kyle M. Pierce, et autres
Publié: (2021)

Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver
par: Xiangdong Ye, et autres
Publié: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
par: Zhitao Li, et autres
Publié: (2021)

The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms
par: Huihui Yin, et autres
Publié: (2021)

Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment
par: Gang Shi, et autres
Publié: (2021)

Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
par: Alyssa Vito, et autres
Publié: (2021)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
par: Laura Jimbu, et autres
Publié: (2021)

Regulatory Mechanism of PD-L1 Expression in Primary Liver Cancer
par: LI Shenghao, et autres
Publié: (2021)

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
par: Melissa L. Bastacky, et autres
Publié: (2021)

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review
par: Haihua He, et autres
Publié: (2021)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
par: Peiyi Xie, et autres
Publié: (2021)

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
par: Xin Cai, et autres
Publié: (2021)

Multi-Omics Analysis of Glioblastoma Cells’ Sensitivity to Oncolytic Viruses
par: Anastasiya V. Lipatova, et autres
Publié: (2021)

Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis
par: Yang You, et autres
Publié: (2021)

Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy
par: Jing Zhou, et autres
Publié: (2022)

PD-1 blockade improves the anti-tumor potency of exhausted CD3+CD56+ NKT-like cells in patients with primary hepatocellular carcinoma
par: Longxiang Tao, et autres
Publié: (2021)

Oncolytic Virotherapy: From Bench to Bedside
par: Ludi Yang, et autres
Publié: (2021)

The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma
par: Georgia Stewart, et autres
Publié: (2021)

Anti-inflammatory components of the Vietnamese starfish Protoreaster nodosus
par: Thao,Nguyen Phuong, et autres
Publié: (2015)

Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
par: Zheng Yan, et autres
Publié: (2021)

IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
par: Xiaoyan Zhang, et autres
Publié: (2021)

Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model
par: Du Y, et autres
Publié: (2017)

Development of approaches for cellular immunotherapy of cancer patients
par: Yu. V. Gelm, et autres
Publié: (2021)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
par: Ye Peng, et autres
Publié: (2021)

Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma
par: Shoh Yajima, et autres
Publié: (2021)

Fatal fulminant HSV-2 myocarditis: A complicated presentation
par: Daniele Colombo, et autres
Publié: (2022)

Correction: IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
Publié: (2021)

Ad-Apoptin-hTERTp-E1a Regulates Autophagy Through the AMPK-mTOR-eIF4F Signaling Axis to Reduce Drug Resistance of MCF-7/ADR Cells
par: Yaru Li, et autres
Publié: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
par: Miao Wang, et autres
Publié: (2021)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
par: I. O. Chikileva, et autres
Publié: (2019)

Obtainingvaccinia virus with increased production of extracellular enveloped virions and directing GM-CSF synthesis as a promising basis for development of antitumor drug
par: T. V. Bauer, et autres
Publié: (2020)

SHORT OVERVIEW OF CLINICAL TRIALS WITH CURRENT IMMUNOTHERAPEUTIC TOOLS FOR CANCER TREATMENT
par: T. S. Nepomnyashchikh, et autres
Publié: (2017)

Improving cancer immunotherapy by targeting IL-1
par: Zhilan Xiao, et autres
Publié: (2021)